A M Vannucchi


Affiliation: University of Florence
Country: Italy


  1. Vannucchi A, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59:171-91 pubmed publisher
    ..In the current article, the authors provide a clinically oriented overview of MPNs in terms of their molecular pathogenesis, classification, diagnosis, and management. ..
  2. request reprint
    Vannucchi A, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21:1952-9 pubmed
    ..001) or developing major cardiovascular events (RR 7.1; P=0.003) during follow up were significantly increased. We conclude that a burden of JAK2(V617F) allele greater than 75% at diagnosis points to PV patients with high-risk disease. ..
  3. Vannucchi A, Te Boekhorst P, Harrison C, He G, Caramella M, Niederwieser D, et al. EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica. 2018;: pubmed publisher
    ..Improvements in the Total Symptom Score were also observed. In this study, ruxolitinib demonstrated acceptable tolerability in both the strata at the maximum safe starting dose of 10 mg twice daily (NCT01317875).  . ..
  4. Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, et al. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Blood Cancer J. 2018;8:122 pubmed publisher
  5. request reprint
    Vannucchi A, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia. 2006;20:1055-60 pubmed
    ..We propose that this method might complement current technologies based on genomic DNA analysis, and lead prospectively to a better clinically oriented assessment of the impact of JAK2(V617F) mutation in MPD. ..
  6. Vannucchi A, Kantarjian H, Kiladjian J, Gotlib J, Cervantes F, Mesa R, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100:1139-45 pubmed publisher
    ..clinicaltrials.gov identifiers: COMFORT-I, NCT00952289; COMFORT-II, NCT00934544). ..
  7. Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299-307 pubmed publisher
  8. Guglielmelli P, Rotunno G, Pacilli A, Vannucchi A. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?. Curr Hematol Malig Rep. 2015;10:380-7 pubmed publisher
    ..This review focuses on current knowledge regarding genotype-prognostic correlates in MF, however, with the understanding that this is a rapid moving field and no definite recommendations for the clinicians can be done yet. ..
  9. request reprint
    Vannucchi A, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840-6 pubmed
    ..We conclude that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET. ..

More Information


  1. Vannucchi A. From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. Haematologica. 2017;102:18-29 pubmed publisher
    ..This review will present a critical overview of evolving concepts in diagnosis and treatment of this disease. ..
  2. Salati S, Prudente Z, Genovese E, Pennucci V, Rontauroli S, Bartalucci N, et al. Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation. Stem Cells Dev. 2017;: pubmed publisher
  3. Vannucchi A, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008;112:844-7 pubmed publisher
    ..These data indicate that MPLW515L/K mutations do not define a distinct phenotype in ET, although some differences depended on the JAK2V617F mutational status of the counterpart. ..
  4. Vannucchi A. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med. 2010;5:177-84 pubmed publisher
  5. Vannucchi A. JAK2 mutation and thrombosis in the myeloproliferative neoplasms. Curr Hematol Malig Rep. 2010;5:22-8 pubmed publisher
    ..It is hoped that elucidation of the role mutant JAK2 plays in MPNs will improve our understanding of the pathophysiology of thrombosis and eventually result in improved patient treatment using molecularly targeted drugs. ..
  6. Vannucchi A, Lasho T, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861-9 pubmed publisher
    ..Mutational profiling for ASXL1, EZH2, SRSF2 and IDH identifies PMF patients who are at risk for premature death or leukemic transformation. ..
  7. Vannucchi A, Pancrazzi A, Guglielmelli P, Di Lollo S, Bogani C, Baroni G, et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol. 2005;167:849-58 pubmed
    ..We conclude that megakaryocytes from IM patients have reduced GATA-1 content, possibly contributing to disease pathogenesis as in the GATA-1(low) mice and also representing a novel IM-associated marker. ..
  8. Vannucchi A, Pieri L, Susini M, Guglielmelli P. BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. Future Oncol. 2012;8:575-93 pubmed publisher
    ..This review discusses how to manage, according to current clinical practice, the steps of diagnosis, prognostication and therapeutic choices in myeloproliferative neoplasm patients...